特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
953486

筋炎治療の世界市場:業界の動向と2027年までの予測

Global Myositis Treatment Market - Industry Trends and Forecast to 2027

出版日: | 発行: Data Bridge Market Research Private Limited | ページ情報: 英文 315 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.45円
筋炎治療の世界市場:業界の動向と2027年までの予測
出版日: 2020年07月01日
発行: Data Bridge Market Research Private Limited
ページ情報: 英文 315 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の筋炎治療市場は、2020年から2027年の予測期間中に6.5%のCAGRで成長すると予測されています。同市場の主な成長要因には、新興の生物学的療法、高齢者人口の増加と炎症の新たな症例などが挙げられます。

当レポートは、世界の筋炎治療市場について調査しており、市場の成長および抑制要因、課題や機会、タイプ・治療エンドユーザー・流通チャネル・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

第2章 市場セグメンテーション

第3章 エグゼクティブサマリー

第4章 パイプライン分析

第5章 疫学

第6章 世界市場:規制

第7章 市場概要

  • 成長要因
    • 高齢者人口の増加と炎症の出現
    • 病気についての認識の高まり
    • 魅力的なサポートと資金調達
    • 新たな生物学的療法
    • 適応外医薬品の入手可能性
  • 抑制要因
    • 封入体筋炎(IBM)に対する効果的な治療の不利用
    • 筋炎の治療に関連する高いコスト
    • 中所得国および低所得国における医療費の不足
  • 市場機会
    • 特定の治療に対する高い需要
    • 有利な償還方針
    • 市場参入企業による戦略的イニシアチブ
    • 新しいパイプライン薬の存在
  • 課題
    • 副腎皮質ホルモン剤と免疫抑制剤別副作用
    • 筋炎治療のためのハーブ薬と鍼の存在
    • 病気症状の診断の不正確さ

第8章 COVID-19パンデミックによる市場への影響

  • 価格の影響
  • サプライチェーンへの影響
  • 需要への影響
  • 製造業者のための戦略的決定
  • 結論

第9章 市場分析:タイプ別

  • 概要
  • 多発性筋炎
  • 皮膚筋炎
  • 封入体筋炎(IBM)
    • 散発性封入体筋炎(S-IBM)
    • 遺伝性封入体ミオパチー(H-IBM)
  • 壊死性ミオパチー
  • 若年性筋炎
  • その他

第10章 市場分析:治療別

  • 概要
  • 投薬
    • 免疫抑制剤
    • コルチコステロイド
    • 免疫グロブリン
  • 治療
    • 理学療法
    • 作業療法
    • 言語療法
    • セルフケア療法
    • その他
  • サプリメント
    • クレアチン一水和物
    • ミトコンドリアカクテル
    • その他

第11章 市場分析:エンドユーザー別

  • 概要
  • 病院
  • 治療センター
  • 専門クリニック
  • ヘルスケア
  • その他

第12章 市場分析:流通チャネル別

  • 概要
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第13章 市場分析:地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • オランダ
    • スペイン
    • ロシア
    • スイス
    • トルコ
    • オーストリア
    • ノルウェー
    • ハンガリー
    • リトアニア
    • アイルランド
    • ポーランド
    • その他
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • シンガポール
    • マレーシア
    • タイ
    • インドネシア
    • フィリピン
    • ベトナム
    • その他
  • 南米
    • ブラジル
    • アルゼンチン
    • ペルー
    • 南米
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • イスラエル
    • エジプト
    • クウェート
    • その他

第14章 世界市場・企業情勢

  • 企業シェア分析:世界
  • 企業シェア分析:北米
  • 企業シェア分析:欧州
  • 企業シェア分析:アジア太平洋地域

第15章 SWOT

第16章 企業プロファイル

  • PFIZER INC.
  • SANDOZ AG (A SUBSIDIARY OF NOVARTIS AG)
  • TEVA PHARMACEUTICAL U.S.A INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
  • MYLAN N.V.
  • GRIFOLS, S.A.
  • CSL BEHRING (A SUBSIDIARY OF CSL)
  • 武田薬品工業株式会社
  • HIKMA PHARMACEUTICALS PLC
  • AMNEAL PHARMACEUTICALS LLC
  • KEDRION BIOPHARMA INC. (A SUBSIDIARY OF KEDRION S.P.A)
  • ABCURO, INC.
  • ACCORD HEALTHCARE
  • ADMA BIOLOGICS, INC.
  • ALZHEON, INC.
  • BIO PRODUCTS LABORATORY LTD.
  • CORBUS PHARMACEUTICALS HOLDINGS, INC.
  • HALOZYME, INC.
  • HORIZON THERAPEUTICS PLC
  • ORPHAZYME A/S
  • ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)

第17章 アンケート

第18章 関連レポート

図表

LIST OF FIGURES

  • FIGURE 1 GLOBAL MYOSITIS TREATMENT MARKET: SEGMENTATION 42
  • FIGURE 2 GLOBAL MYOSITIS TREATMENT MARKET : DATA TRIANGULATION 45
  • FIGURE 3 GLOBAL MYOSITIS TREATMENT MARKET: DROC ANALYSIS 46
  • FIGURE 4 GLOBAL MYOSITIS TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 47
  • FIGURE 5 GLOBAL MYOSITIS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 47
  • FIGURE 6 GLOBAL MYOSITIS TREATMENT MARKET: MULTIVARIATE MODELLING 48
  • FIGURE 7 GLOBAL MYOSITIS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 49
  • FIGURE 8 GLOBAL MYOSITIS TREATMENT MARKET: DBMR MARKET POSITION GRID 50
  • FIGURE 9 GLOBAL MYOSITIS TREATMENT MARKET: VENDOR SHARE ANALYSIS 51
  • FIGURE 10 GLOBAL MYOSITIS TREATMENT MARKET: SEGMENTATION 55
  • FIGURE 11 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL MYOSITIS TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 56
  • FIGURE 12 RISING GERIATRIC POPULATION AND EMERGING CASES OF INFLAMMATION AND RISING AWARENESS ABOUT THE DISEASE IS DRIVING THE GLOBAL MYOSITIS TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 57
  • FIGURE 13 POLYMYOSITIS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL MYOSITIS TREATMENT MARKET IN 2020 & 2027 57
  • FIGURE 14 NORTH AMERICA IS THE FASTEST GROWING MARKET FOR MYOSITIS TREATMENT DRUGS MANUFACTURERS IN THE FORECAST PERIOD OF 2020 TO 2027 58
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL MYOSITIS TREATMENT MARKET 63
  • FIGURE 16 GLOBAL MYOSITIS TREATMENT MARKET: BY TYPE, 2019 75
  • FIGURE 17 GLOBAL MYOSITIS TREATMENT MARKET: BY TYPE, 2019-2027 (USD MILLION) 76
  • FIGURE 18 GLOBAL MYOSITIS TREATMENT MARKET: BY TYPE, CAGR (2020-2027) 76
  • FIGURE 19 GLOBAL MYOSITIS TREATMENT MARKET: BY TYPE, LIFELINE CURVE 77
  • FIGURE 20 GLOBAL MYOSITIS TREATMENT MARKET: BY TREATMENT, 2019 84
  • FIGURE 21 GLOBAL MYOSITIS TREATMENT MARKET: BY TREATMENT, 2019-2027 (USD MILLION) 85
  • FIGURE 22 GLOBAL MYOSITIS TREATMENT MARKET: BY TREATMENT, CAGR (2020-2027) 85
  • FIGURE 23 GLOBAL MYOSITIS TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE 86
  • FIGURE 24 GLOBAL MYOSITIS TREATMENT MARKET: BY END USER, 2019 95
  • FIGURE 25 GLOBAL MYOSITIS TREATMENT MARKET: BY END USER, 2019-2027 (USD MILLION) 96
  • FIGURE 26 GLOBAL MYOSITIS TREATMENT MARKET: BY END USER, CAGR (2020-2027) 96
  • FIGURE 27 GLOBAL MYOSITIS TREATMENT MARKET: BY END USER, LIFELINE CURVE 97
  • FIGURE 28 GLOBAL MEDICATION & SUPPLEMENTS IN MYOSITIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019 103
  • FIGURE 29 GLOBAL MEDICATION & SUPPLEMENTS IN MYOSITIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION) 104
  • FIGURE 30 GLOBAL MEDICATION & SUPPLEMENTS IN MYOSITIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027) 104
  • FIGURE 31 GLOBAL MEDICATION & SUPPLEMENTS IN MYOSITIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 105
  • FIGURE 32 GLOBAL MYOSITIS TREATMENT MARKET: SNAPSHOT (2019) 110
  • FIGURE 33 GLOBAL MYOSITIS TREATMENT MARKET: BY REGION (2019) 111
  • FIGURE 34 GLOBAL MYOSITIS TREATMENT MARKET: BY REGION (2020 & 2027) 111
  • FIGURE 35 GLOBAL MYOSITIS TREATMENT MARKET: BY REGION (2019 & 2027) 112
  • FIGURE 36 GLOBAL MYOSITIS TREATMENT MARKET: BY PRODUCT (2020-2027) 112
  • FIGURE 37 NORTH AMERICA MYOSITIS TREATMENT MARKET: SNAPSHOT (2019) 114
  • FIGURE 38 NORTH AMERICA MYOSITIS TREATMENT MARKET: BY COUNTRY (2019) 115
  • FIGURE 39 NORTH AMERICA MYOSITIS TREATMENT MARKET: BY COUNTRY (2020 & 2027) 115
  • FIGURE 40 NORTH AMERICA MYOSITIS TREATMENT MARKET: BY COUNTRY (2019 & 2027) 116
  • FIGURE 41 NORTH AMERICA MYOSITIS TREATMENT MARKET: BY TYPE (2020-2027) 116
  • FIGURE 42 EUROPE MYOSITIS TREATMENT MARKET: SNAPSHOT (2019) 130
  • FIGURE 43 EUROPE MYOSITIS TREATMENT MARKET: BY COUNTRY (2019) 131
  • FIGURE 44 EUROPE MYOSITIS TREATMENT MARKET: BY COUNTRY (2020 & 2027) 131
  • FIGURE 45 EUROPE MYOSITIS TREATMENT MARKET: BY COUNTRY (2019 & 2027) 132
  • FIGURE 46 EUROPE MYOSITIS TREATMENT MARKET: BY TYPE (2020-2027) 132
  • FIGURE 47 ASIA- PACIFIC MYOSITIS TREATMENT MARKET: SNAPSHOT (2019) 183
  • FIGURE 48 ASIA- PACIFIC MYOSITIS TREATMENT MARKET: BY COUNTRY (2019) 184
  • FIGURE 49 ASIA- PACIFIC MYOSITIS TREATMENT MARKET: BY COUNTRY (2020 & 2027) 184
  • FIGURE 50 ASIA- PACIFIC MYOSITIS TREATMENT MARKET: BY COUNTRY (2019 & 2027) 185
  • FIGURE 51 ASIA- PACIFIC MYOSITIS TREATMENT MARKET: BY TYPE (2020-2027) 185
  • FIGURE 52 SOUTH AMERICA MYOSITIS TREATMENT MARKET: SNAPSHOT (2019) 224
  • FIGURE 53 SOUTH AMERICA MYOSITIS TREATMENT MARKET: BY COUNTRY (2019) 225
  • FIGURE 54 SOUTH AMERICA MYOSITIS TREATMENT MARKET: BY COUNTRY (2020 & 2027) 225
  • FIGURE 55 SOUTH AMERICA MYOSITIS TREATMENT MARKET: BY COUNTRY (2019 & 2027) 226
  • FIGURE 56 SOUTH AMERICA MYOSITIS TREATMENT MARKET: BY TYPE (2020-2027) 226
  • FIGURE 57 MIDDLE EAST & AFRICA MYOSITIS TREATMENT MARKET: SNAPSHOT (2019) 241
  • FIGURE 58 MIDDLE EAST & AFRICA MYOSITIS TREATMENT MARKET: BY COUNTRY (2019) 242
  • FIGURE 59 MIDDLE EAST & AFRICA MYOSITIS TREATMENT MARKET: BY COUNTRY (2020 & 2027) 242
  • FIGURE 60 MIDDLE EAST & AFRICA MYOSITIS TREATMENT MARKET: BY COUNTRY (2019 & 2027) 243
  • FIGURE 61 MIDDLE EAST & AFRICA MYOSITIS TREATMENT MARKET: BY TYPE (2020-2027) 243
  • FIGURE 62 GLOBAL MYOSITIS TREATMENT MARKET: COMPANY SHARE 2019 (%) 267
  • FIGURE 63 NORTH AMERICA MYOSITIS TREATMENT MARKET: COMPANY SHARE 2019 (%) 268
  • FIGURE 64 EUROPE MYOSITIS TREATMENT MARKET: COMPANY SHARE 2019 (%) 269
  • FIGURE 65 ASIA-PACIFIC MYOSITIS TREATMENT MARKET: COMPANY SHARE 2019 (%) 270
目次

Global myositis treatment market is projected to register a CAGR of 6.5% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation:

Global Myositis Treatment Market, By Type (Polymyositis, Dermatomyositis, Inclusion Body Myositis (IBM), Necrotizing Myopathy, Juvenile Myositis, Others), Treatment (Medication, Therapy, Supplements), End User (Hospitals, Therapy Centers, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Russia, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland and rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam and rest of Asia-Pacific, Brazil, Argentina, Peru and rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Egypt, Kuwait and rest of Middle East and Africa) Industry Trends and Forecast to 2027

Some of the major factors contributing to the growth of global myositis treatment market are:

Emerging biological therapies

Rising geriatric population and emerging cases of inflammation

Market Players

The key market players for global myositis treatment market are listed below:

ADMA Biologics, Inc.

CSL Behring (A Subsidiary of CSL)

Takeda Pharmaceutical Company Limited

Teva Pharmaceutical USA Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.)

Hikma Pharmaceuticals PLC

Mylan N.V.

Pfizer Inc.

Zydus Pharmaceuticals, Inc. (A Subsidiary of Zydus Cadila)

Amneal Pharmaceuticals LLC

Horizon Therapeutics plc

Grifols, S.A.

Kedrion Biopharma Inc. (A Subsidiary of Kedrion S.p.A)

Bio Products Laboratory Ltd.

Halozyme, Inc.

ORPHAZYME A/S

Alzheon, Inc.

Abcuro, Inc.

Corbus Pharmaceuticals Holdings, Inc.

Accord Healthcare

Sandoz AG (A Subsidiary of Novartis AG)

TABLE OF CONTENTS

1 INTRODUCTION 37

  • 1.1 OBJECTIVES OF THE STUDY 37
  • 1.2 MARKET DEFINITION 37
  • 1.3 OVERVIEW OF GLOBAL MYOSITIS TREATMENT MARKET 37
  • 1.4 LIMITATIONS 39
  • 1.5 MARKETS COVERED 39

2 MARKET SEGMENTATION 42

  • 2.1 MARKETS COVERED 42
  • 2.2 GEOGRAPHICAL SCOPE 43
  • 2.3 YEARS CONSIDERED FOR THE STUDY 44
  • 2.4 CURRENCY AND PRICING 44
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 45
  • 2.6 MULTIVARIATE MODELLING 48
  • 2.7 TYPE LIFELINE CURVE 48
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 49
  • 2.9 DBMR MARKET POSITION GRID 50
  • 2.10 VENDOR SHARE ANALYSIS 51
  • 2.11 SECONDARY SOURCES 52
  • 2.12 ASSUMPTIONS 52

3 EXECUTIVE SUMMARY 53

4 PIPELINE ANALYSIS 59

5 EPIDEMIOLOGY 60

6 GLOBAL MYOSITIS TREATMENT MARKET: REGULATIONS 61

7 MARKET OVERVIEW 62

  • 7.1 DRIVERS 64
    • 7.1.1 RISING GERIATRIC POPULATION AND EMERGING CASES OF INFLAMMATION 64
    • 7.1.2 RISING AWARENESS ABOUT THE DISEASE 64
    • 7.1.3 ATTRACTIVE SUPPORT AND FUNDING 65
    • 7.1.4 EMERGING BIOLOGICAL THERAPIES 65
    • 7.1.5 AVAILABILITY OF OFF LABEL DRUGS 66
  • 7.2 RESTRAINTS 67
    • 7.2.1 UNAVAILABILITY OF EFFECTIVE TREATMENT FOR INCLUSION BODIES MYOSITIS (IBM) 67
    • 7.2.2 HIGH COST ASSOCIATED WITH TREATMENT OF MYOSITIS 67
    • 7.2.3 LACK OF HEALTHCARE EXPENDITURE IN MIDDLE INCOME AND LOW INCOME COUNTRIES 68
  • 7.3 OPPORTUNITIES 68
    • 7.3.1 HIGH DEMAND OF DISEASE SPECIFIC TREATMENT 68
    • 7.3.2 FAVOURABLE REIMBURSEMENT POLICIES 69
    • 7.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 69
    • 7.3.4 PRESENCE OF NOVEL PIPELINE DRUGS 70
  • 7.4 CHALLENGES 70
    • 7.4.1 SIDE EFFECTS CAUSED BY CORTICOSTEROIDS AND IMMUNOSUPPRESSANTS DRUGS 70
    • 7.4.2 EXISTENCE OF HERBAL MEDICINES AND ACUPUNCTURE FOR MYOSITIS TREATMENT 71
    • 7.4.3 INABILITY TO ACCURATELY DIAGNOSE THE DISEASE SYMPTOMS 71

8 IMPACT OF COVID-19 PANDEMIC ON THE GLOBAL MYOSITIS TREATMENT MARKET 72

  • 8.1 PRICE IMPACT 72
  • 8.2 IMPACT ON SUPPLY CHAIN 72
  • 8.3 IMPACT ON DEMAND 73
  • 8.4 STRATEGIC DECISIONS FOR MANUFACTURERS 73
  • 8.5 CONCLUSION 73

9 GLOBAL MYOSITIS TREATMENT MARKET, BY TYPE 74

  • 9.1 OVERVIEW 75
  • 9.2 POLYMYOSITIS 78
  • 9.3 DERMATOMYOSITIS 78
  • 9.4 INCLUSION BODY MYOSITIS (IBM) 79
    • 9.4.1 SPORADIC INCLUSION BODY MYOSITIS (S-IBM) 80
    • 9.4.2 HEREDITARY INCLUSION BODY MYOPATHY (H-IBM) 80
  • 9.5 NECROTIZING MYOPATHY 80
  • 9.6 JUVENILE MYOSITIS 81
  • 9.7 OTHERS 82

10 GLOBAL MYOSITIS TREATMENT MARKET, BY TREATMENT 83

  • 10.1 OVERVIEW 84
  • 10.2 MEDICATION 87
    • 10.2.1 IMMUNOSUPPRESSANTS 87
      • 10.2.1.1 METHOTREXATE 88
      • 10.2.1.2 AZATHIOPRINE 88
      • 10.2.1.3 MYCOPHENOLATE MOFETIL 88
      • 10.2.1.4 CYCLOPHOSPHAMIDE 88
      • 10.2.1.5 TACROLIMUS 88
      • 10.2.1.6 CYCLOSPORINE 88
      • 10.2.1.7 HYDROXYCHLOROQUINE 88
      • 10.2.1.8 OTHERS 89
    • 10.2.2 CORTICOSTEROIDS 89
      • 10.2.2.1 PREDNISONE 89
      • 10.2.2.2 PREDNISOLONE 89
      • 10.2.2.3 METHYLPREDNISOLONE 89
      • 10.2.2.4 ADRENOCORTICOTROPIC HORMONE (ACTH) 89
      • 10.2.2.5 OTHERS 89
    • 10.2.3 IMMUNOGLOBULINS 90
      • 10.2.3.1 IMMUNE GLOBULINS INTRAVENOUS 90
      • 10.2.3.2 IMMUNE GLOBULINS SUBCUTANEOUS 90
      • 10.2.3.3 OTHERS 90
  • 10.3 THERAPY 90
    • 10.3.1 PHYSICAL THERAPY 91
    • 10.3.2 OCCUPATIONAL THERAPY 91
    • 10.3.3 SPEECH THERAPY 91
    • 10.3.4 SELF-CARE THERAPY 91
    • 10.3.5 OTHERS 92
  • 10.4 SUPPLEMENTS 92
    • 10.4.1 CREATINE MONOHYDRATE 93
    • 10.4.2 MITOCHONDRIAL COCKTAIL 93
    • 10.4.3 OTHERS 93

11 GLOBAL MYOSITIS TREATMENT MARKET, BY END USER 94

  • 11.1 OVERVIEW 95
  • 11.2 HOSPITALS 98
  • 11.3 THERAPY CENTERS 98
  • 11.4 SPECIALTY CLINICS 99
  • 11.5 HOME HEALTHCARE 100
  • 11.6 OTHERS 100

12 GLOBAL MEDICATION & SUPPLEMENTS IN MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 102

  • 12.1 OVERVIEW 103
  • 12.2 HOSPITAL PHARMACIES 105
  • 12.3 RETAIL PHARMACIES 106
  • 12.4 ONLINE PHARMACIES 107

13 GLOBAL MYOSITIS TREATMENT MARKET, BY GEOGRAPHY 108

  • 13.1 OVERVIEW 109
  • 13.2 NORTH AMERICA 114
    • 13.2.1 U.S. 121
    • 13.2.2 CANADA 124
    • 13.2.3 MEXICO 127
  • 13.3 EUROPE 130
    • 13.3.1 GERMANY 137
    • 13.3.2 FRANCE 140
    • 13.3.3 U.K. 143
    • 13.3.4 ITALY 146
    • 13.3.5 NETHERLANDS 149
    • 13.3.6 SPAIN 152
    • 13.3.7 RUSSIA 155
    • 13.3.8 SWITZERLAND 158
    • 13.3.9 TURKEY 161
    • 13.3.10 AUSTRIA 164
    • 13.3.11 NORWAY 167
    • 13.3.12 HUNGARY 170
    • 13.3.13 LITHUANIA 173
    • 13.3.14 IRELAND 176
    • 13.3.15 POLAND 179
    • 13.3.16 REST OF EUROPE 182
  • 13.4 ASIA- PACIFIC 183
    • 13.4.1 JAPAN 190
    • 13.4.2 CHINA 193
    • 13.4.3 INDIA 196
    • 13.4.4 SOUTH KOREA 199
    • 13.4.5 AUSTRALIA 202
    • 13.4.6 SINGAPORE 205
    • 13.4.7 MALAYSIA 208
    • 13.4.8 THAILAND 211
    • 13.4.9 INDONESIA 214
    • 13.4.10 PHILIPPINES 217
    • 13.4.11 VIETNAM 220
    • 13.4.12 REST OF ASIA-PACIFIC 223
  • 13.5 SOUTH AMERICA 224
    • 13.5.1 BRAZIL 231
    • 13.5.2 ARGENTINA 234
    • 13.5.3 PERU 237
    • 13.5.4 REST OF SOUTH AMERICA 240
  • 13.6 MIDDLE EAST & AFRICA 241
    • 13.6.1 SAUDI ARABIA 248
    • 13.6.2 SOUTH AFRICA 251
    • 13.6.3 UAE 254
    • 13.6.4 ISRAEL 257
    • 13.6.5 EGYPT 260
    • 13.6.6 KUWAIT 263
    • 13.6.7 REST OF MIDDLE EAST & AFRICA 266

14 GLOBAL MYOSITIS TREATMENT MARKET, COMPANY LANDSCAPE 267

  • 14.1 COMPANY SHARE ANALYSIS: GLOBAL 267
  • 14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 268
  • 14.3 COMPANY SHARE ANALYSIS: EUROPE 269
  • 14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 270

15 SWOT 271

16 COMPANY PROFILES 272

  • 16.1 PFIZER INC. 272
    • 16.1.1 COMPANY SNAPSHOT 272
    • 16.1.2 REVENUE ANALYSIS 272
    • 16.1.3 COMPANY SHARE ANALYSIS 273
    • 16.1.4 PRODUCT PORTFOLIO 273
    • 16.1.5 RECENT DEVELOPMENTS 273
  • 16.2 SANDOZ AG (A SUBSIDIARY OF NOVARTIS AG) 274
    • 16.2.1 COMPANY SNAPSHOT 274
    • 16.2.2 REVENUE ANALYSIS 274
    • 16.2.3 COMPANY SHARE ANALYSIS 275
    • 16.2.4 PRODUCT PORTFOLIO 275
    • 16.2.5 RECENT DEVELOPMENTS 275
  • 16.3 TEVA PHARMACEUTICAL U.S.A INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.) 277
    • 16.3.1 COMPANY SNAPSHOT 277
    • 16.3.2 REVENUE ANALYSIS 277
    • 16.3.3 COMPANY SHARE ANALYSIS 278
    • 16.3.4 PRODUCT PORTFOLIO 278
    • 16.3.5 RECENT DEVELOPMENTS 278
  • 16.4 MYLAN N.V. 280
    • 16.4.1 COMPANY SNAPSHOT 280
    • 16.4.2 REVENUE ANALYSIS 280
    • 16.4.3 COMPANY SHARE ANALYSIS 281
    • 16.4.4 PRODUCT PORTFOLIO 281
    • 16.4.5 RECENT DEVELOPMENTS 281
  • 16.5 GRIFOLS, S.A. 283
    • 16.5.1 COMPANY SNAPSHOT 283
    • 16.5.2 REVENUE ANALYSIS 283
    • 16.5.3 PRODUCT PORTFOLIO 284
    • 16.5.4 RECENT DEVELOPMENTS 284
  • 16.6 CSL BEHRING (A SUBSIDIARY OF CSL) 286
    • 16.6.1 COMPANY SNAPSHOT 286
    • 16.6.2 REVENUE ANALYSIS 286
    • 16.6.3 PRODUCT PORTFOLIO 287
    • 16.6.4 RECENT DEVELOPMENTS 287
  • 16.7 TAKEDA PHARMACEUTICAL COMPANY LIMITED 288
    • 16.7.1 COMPANY SNAPSHOT 288
    • 16.7.2 REVENUE ANALYSIS 289
    • 16.7.3 PRODUCT PORTFOLIO 289
    • 16.7.4 RECENT DEVELOPMENTS 289
  • 16.8 HIKMA PHARMACEUTICALS PLC 291
    • 16.8.1 COMPANY SNAPSHOT 291
    • 16.8.2 REVENUE ANALYSIS 291
    • 16.8.3 PRODUCT PORTFOLIO 292
    • 16.8.4 RECENT DEVELOPMENTS 292
  • 16.9 AMNEAL PHARMACEUTICALS LLC 293
    • 16.9.1 COMPANY SNAPSHOT 293
    • 16.9.2 REVENUE ANALYSIS 293
    • 16.9.3 PRODUCT PORTFOLIO 293
    • 16.9.4 RECENT DEVELOPMENTS 294
  • 16.10 KEDRION BIOPHARMA INC. (A SUBSIDIARY OF KEDRION S.P.A) 295
    • 16.10.1 COMPANY SNAPSHOT 295
    • 16.10.2 REVENUE ANALYSIS 295
    • 16.10.3 PRODUCT PORTFOLIO 296
    • 16.10.4 RECENT DEVELOPMENTS 296
  • 16.11 ABCURO, INC. 297
    • 16.11.1 COMPANY SNAPSHOT 297
    • 16.11.2 PRODUCT PORTFOLIO 297
    • 16.11.3 RECENT DEVELOPMENT 297
  • 16.12 ACCORD HEALTHCARE 298
    • 16.12.1 COMPANY SNAPSHOT 298
    • 16.12.2 PRODUCT PORTFOLIO 298
    • 16.12.3 RECENT DEVELOPMENTS 298
  • 16.13 ADMA BIOLOGICS, INC. 299
    • 16.13.1 COMPANY SNAPSHOT 299
    • 16.13.2 REVENUE ANALYSIS 299
    • 16.13.3 PRODUCT PORTFOLIO 300
    • 16.13.4 RECENT DEVELOPMENTS 300
  • 16.14 ALZHEON, INC. 301
    • 16.14.1 COMPANY SNAPSHOT 301
    • 16.14.2 PRODUCT PORTFOLIO 301
    • 16.14.3 RECENT DEVELOPMENT 301
  • 16.15 BIO PRODUCTS LABORATORY LTD. 302
    • 16.15.1 COMPANY SNAPSHOT 302
    • 16.15.2 PRODUCT PORTFOLIO 302
    • 16.15.3 RECENT DEVELOPMENTS 302
  • 16.16 CORBUS PHARMACEUTICALS HOLDINGS, INC. 303
    • 16.16.1 COMPANY SNAPSHOT 303
    • 16.16.2 PRODUCT PORTFOLIO 303
    • 16.16.3 RECENT DEVELOPMENTS 304
  • 16.17 HALOZYME, INC. 305
    • 16.17.1 COMPANY SNAPSHOT 305
    • 16.17.2 REVENUE ANALYSIS 305
    • 16.17.3 PRODUCT PORTFOLIO 306
    • 16.17.4 RECENT DEVELOPMENTS 306
  • 16.18 HORIZON THERAPEUTICS PLC 307
    • 16.18.1 COMPANY SNAPSHOT 307
    • 16.18.2 REVENUE ANALYSIS 307
    • 16.18.3 PRODUCT PORTFOLIO 308
    • 16.18.4 RECENT DEVELOPMENTS 308
  • 16.19 ORPHAZYME A/S 309
    • 16.19.1 COMPANY SNAPSHOT 309
    • 16.19.2 PRODUCT PORTFOLIO 309
    • 16.19.3 RECENT DEVELOPMENT 309
  • 16.20 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA) 310
    • 16.20.1 COMPANY SNAPSHOT 310
    • 16.20.2 REVENUE ANALYSIS 310
    • 16.20.3 PRODUCT PORTFOLIO 311
    • 16.20.4 RECENT DEVELOPMENTS 311

17 QUESTIONNAIRE 312

18 RELATED REPORTS 315

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.